Anti-Hib PS antibodies bearing Hibld-1 were present in at least 85% of subjects immunized with either free Hib PS or Hib PS coupled to diphtheria toxoid (Hib PS-DT), and comprised on the average 60% ofthe total vaccine-induced serum anti-Hib PS. Hibld-1 expression was not related to age at vaccination inasmuch as infants, children, and adults had similar distributions of Hibld-1-positive anti-Hib PS after vaccination with Hib PS-DT. HibId-1 was expressed at a lower frequency and comprised a smaller fraction of the total anti-Hib PS antibody in adult preimmunization sera as compared to post-Hib PS immunization sera, suggesting that immunization preferentially Some ofthe results reported here were presented at thejoint meeting of the
Introduction
Haemophilus influenzae type b (Hib)' is an encapsulated bacterium that causes serious invasive disease, particularly among young children (1, 2) . The capsular polysaccharide ofHib (Hib PS), which consists ofrepeating units of 3-(3-D-ribose-( 1-1)-ribitol-5-phosphate, is a major virulence factor, and antibodies specific for the Hib PS confer protection against Hib disease. Like many bacterial polysaccharides, Hib PS is poorly immunogenic in children less than 2 y of age (3) , but conjugation of protein to Hib PS markedly increases its immunogenicity (4, 5) . Immunization of infants as young as 2-4 mo of age with Hib PS conjugate vaccines induces significant levels of serum anti-Hib PS antibody (6, 7) , and probably results in protective immunity.
While the use ofconjugate vaccines offers great promise for the prevention ofinvasive Hib disease, much still remains to be learned about immunity to Hib PS. For example, there is considerable variability in the antibody responses induced by different Hib PS vaccines. Some individuals develop invasive Hib disease despite vaccination (8) , and some conjugate vaccines may be poorly immunogenic or of low efficacy in particular ethnic groups (9, 10) . Furthermore, the protective ability of human anti-Hib PS antibodies may be variable since differences in antibody functional activity and avidity have been described (1 1, 12) . One approach that may elucidate the mechanisms of these functional differences is dissection of the variable (V) region repertoire ofHib PS-specific antibodies. Definition of anti-Hib PS V regions may make it possible to draw V region structure/function correlates. Furthermore, such definition should allow examination of the genetic and environmental factors that influence anti-Hib PS antibody V region repertoire expression.
Serological characterization ofanti-Hib PS V regions using polyclonal anti-idiotypic reagents has shown that most individuals express a shared, cross-reactive idiotype (CRI) that comprises a significant portion ofthe total serum anti-Hib PS antibody (13, 14) . These findings indicate pauciclonality and lim-ited anti-Hib PS V region heterogeneity. Moreover, the occurrence ofa prevalent CRI in unrelated individuals suggests that structurally conserved V genes may encode a substantial part ofthe expressed anti-Hib PS repertoire. However, the precision of the idiotypic analyses has been limited by the use of polyclonal anti-CRI reagents, and by the lack of information regarding the structural correlate of the CRI.
A more definitive albeit limited approach to the repertoire has been the molecular characterization of clonally purified anti-Hib PS antibodies from multiple individuals (15 -17) . These studies have established that anti-Hib PS VH regions are ofthe VHIII subgroup, whereas the VL regions may be VX, VKI, VKIII, or most commonly VKII. Remarkably, the V regions of all VKII antibodies described to date are derived from the VKII gene, A2, and contain little or no somatic mutation in complementarity determining regions (17) . However, although sequencing has directly identified particular V regions, this approach is clearly not amenable for the analysis of serum antibodies in large populations. A combined approach in which anti-idiotypic reagents are used with sequence-defined antiHib PS antibodies, allows for the molecular characterization of CRI determinants, and also provides a convenient and powerful means to examine V region utilization in immune responses to the different Hib PS vaccines in large populations. Here, we report the isolation of a monoclonal antibody (MAb) specific for a CRI expressed by the VKIIA2 L chain ofanti-Hib PS antibodies. Antibodies bearing this VKII CRI are present in most vaccinated infants, children, and adults, and comprise on the average, more than half of the serum antibody to Hib PS.
Methods
Subjects and vaccinations. Sera from 69 healthy children and 91 healthy adults who were immunized with either one dose of Hib PS vaccine (22 children and 66 adults) or with a single dose ofa conjugate vaccine consisting ofHib PS coupled to diphtheria toxoid (Hib PS-DT, Connaught Laboratories, Swiftwater, PA) (47 children and 25 adults), were available for study. Serum samples were obtained immediately before immunization and 1-2 mo after immunization. The majority of these subjects have been described in a previous report ( 14) . The principal criteria for inclusion of subjects were the availability of sufficient sera, and the presence of a twofold or greater increase in anti-Hib PS antibody level after vaccination. The only exceptions were four adults, who had > 1 gg/ml of anti-Hib PS antibody in postvaccination sera, but in whom prevaccination sera were not available.
Anti-Hib PS antibody assays. Total antibody to Hib PS was measured using radioantigen binding assays (RABAs) with '25I-labeled Hib PS as previously described (18, 19) , except that precipitates rather than supernatants were counted. Antibody concentrations were determined from a standard curve generated using dilutions of the U. S. Office of Biologics serum reference pool.
Isolation (20) or to the formal translation products of VK genes (17, 21) for subgroup assignment. Production of MAb anti-CRI. IgG Anti-Hib PS antibodies were purified from the post-Hib PS vaccination sera oftwo subjects (20966 and 24604, expressing high levels of CRI as determined with the goat polyclonal anti-CRI reagent) by affinity chromatography (13) . Individual BALB/c mice were immunized in several subcutaneous sites with 20 ,ug of subject 20966 IgG anti-Hib PS emulsified in complete Freund's adjuvant. 3 wk later the mice were immunized with the same antigen and dose in incomplete Freund's adjuvant. A third injection of subject 24604 anti-Hib PS in incomplete Freund's adjuvant was given -6 wk later. Sera were obtained 10-14 d after the third injection and tested for anti-CRI activity by measuring the ability to inhibit '25I-Hib PS binding of subject 24604 anti-Hib PS antibodies (see below). The mouse having the highest serum inhibition titer was immunized intraperitoneally (3 wk after the third injection) with a mixture of 10 gg of subject 20966 and 10 Mg of subject 24604 anti-Hib PS in saline. 3 d later the spleen was taken and used for hybridoma production. Hybridomas were prepared using established methods (22), by fusing spleen cells to the X63-Ag8.653 cell line (23) with 50% polyethylene glycol. Supernatants were screened for anti-CRI activity by measuring the ability of the supernatant to inhibit 125I-Hib PS binding of solid-phase adsorbed anti-Hib PS antibodies (see below). After subcloning by limiting dilution, a hybridoma clone, designated LuC9 was isolated that secreted MAb capable ofinhibiting '251I-Hib PS binding by anti-Hib PS antibodies isolated from subjects 20966, 24604, and 21411. MAb was isolated from ascites fluid by ammonium sulfate fractionation and ion exchange chromatography. Alkaline phosphatase (Sigma Chemical Co., St. Louis, MO) was coupled to MAb LuC9 using glutaraldehyde.
Assays for MAb anti-CRI. Hybridoma culture supernatants were screened for anti-CRI activity by measuring the ability ofsupernatants to inhibit the capture of '251-Hib PS by solid-phase adsorbed anti-Hib PS antibodies. Wells ofpolyvinyl chloride microtiter plates were coated with subject 21411 IgG anti-Hib PS, 2 ug/ml in PBS, overnight at room temperature. Wells were blocked with BSA, washed with PBSTween, and then incubated with culture supernatant. After 3 h at 37°C, half of the supernatant was withdrawn, and '251-Hib PS (1 X I0O cpm/ well) was added. Plates were incubated for 3 h at 37°C, then washed with PBS-Tween. Wells were excised and bound cpm were determined.
Approximately 3 X 104 cpm of '251-Hib PS was bound in the presence of culture medium alone whereas wells incubated with supernatants having high inhibitory activity had 1-2 X I03 cpm bound.
An ELISA was used to measure the binding of MAb anti-CRI (LuC9) to human Ig. Microtiter wells were coated with 2 Mg/ml of either affinity-purified anti-Hib PS, myeloma proteins (provided by Dr. Hans Spiegelberg, University of California, San Diego), serum y-globulin fractions absorbed with Hib PS-Sepharose, human antiHib PS MAbs ED.8 (IgM, K) or LSF-2 (IgA, X) (provided by Dr. Penelope Shackelford, Washington University School of Medicine, St. Louis, MO), or human intravenous -y-globulin (Sandoglobulin, Sandoz Pharmaceuticals Corp., East Hanover, NJ) absorbed with Hib PSSepharose. After incubation at room temperature overnight, the wells were blocked with BSA and washed with PBS-Tween. Dilutions of alkaline phosphatase-conjugated LuC9 were added to wells and incubated at 37°C for 3 h. Wells were then washed, and p-nitrophenyl phosphate (1 mg/ml diethanolamine buffer, pH 9.5) solution was added. Optical density at 405 nm was determined after -30 min.
Assay ofserum anti-Hib PS CRI expression byanti-CRI inhibition of Hib PS binding. CRI expression by anti-Hib PS antibodies was quantified by measuringthe ability ofeither MAb LuC9 or goat polyclonal anti-CRI, to inhibit Hib PS binding activity in the RABA. This method has been previously described in detail using the polyclonal anti-CRI antibody (14) . Briefly, a dilution of human serum or a dilution of human anti-Hib PS MAb, equivalent to an anti-Hib PS antibody concentration of 200 ng/ml was mixed with either MAb LuC9 (60 yg/ml) or diluent. The mixtures were incubated for 2 hat 37°C and overnight at 40C. Each sample was then divided into two aliquots to which 125I-Hib PS was added. The samples were incubated for 4 h at 370C and 1 h at 4VC. Saturated ammonium sulfate was added with mixing to a final concentration of 50% saturation, and after 2 h at 4VC, the precipitates were harvested by centrifugation (16,000 g), washed one time with 50% saturated ammonium sulfate, and then counted in a dry well y counter. Background counts per minute (i.e., '23I-Hib PS precipitated in the presence of MAb LuC9 or diluent alone, which was < 5% of the total added cpm), were subtracted from the respective means of duplicate determinations. Inhibition of Hib PS binding was calculated as previously described ( 14) .
Hib PS inhibition ofMAb LuC9 binding to anti-Hib PS antibodies. Wells ofmicrotiter plates were coated with either affinity-purified antiHib PS or human MAb ED.8, then blocked with BSA. Purified Hib PS (provided by Dr. Porter Anderson, University of Rochester School of Medicine, Rochester, NY), diluted in BSA-PBS, or BSA-PBS alone, was added to wells for 3 h at 370C. Halfofthe solution was withdrawn and alkaline phosphatase-conjugated LuC9 (1:20,000 dilution) was added to the wells. After 3 h at 370C, the wells were washed andp-nitrophenyl phosphate in diethanolamine buffer was added. Optical density at 405 nm was determined at -30 min. The percent inhibition of MAb LuC9 binding was calculated as previously described (14) .
Western blot analysis ofMAb Luc9 binding to anti-HibPSHandL chains. 3-5 ug of clonally purified anti-Hib PS antibodies were subjected to SDS-PAGE (10% acrylamide) under reducing conditions and electrically blotted onto polyvinylidene difluoride membrane as previously described (16, 17) . Blots were blocked with 2% BSA-1% nonfat dry milk-PBS and subsequently overlayed for 1 h with a 2 Ag/ml solution of either MAb LuC9 or murine MAb HK-2 which is specific for human K chains. After washing with BSA-PBS, blots were reacted for 1 h with '251-labeled anti-murine K chain antibody (MAb 187), then washed, dried, and exposed to X-Omat film (Eastman Kodak Co., Rochester, NY).
Results
Isolation of MAb anti-CRI that inhibits Hib PS binding. To establish that this assay was providing reliable quantita- tive data, we compared the results obtained in this assay with a second method of measuring anti-Hib PS Hibld-I expression. Sera from 11 adults, who had been immunized with Hib PS, were absorbed with either LuC9-agarose or with agarose coupled with an irrelevant murine IgGl, K MAb. The percent specific decrease in the anti-Hib PS antibody level by LuC9-agarose was then determined using the RABA. The Hibld-l antiHib PS values (which ranged from 2% to 100% for individual sera) obtained in the inhibition ofHib PS binding assay were in excellent agreement with those obtained by specific absorption (r = 0.99, m = 1.02). Thus the RABA inhibition assay was suitable for quantifying the fraction ofthe total serum anti-Hib PS that expressed HibId-1.
MAb LuC9 binds to some anti-Hib PS antibodies but not to Ig isotypic determinants. An ELISA was used to examine further the specificity of MAb LuC9. Wells of microtiter plates were coated with various Ig preparations then reacted with alkaline phosphatase-coupled LuC9. Fig. 2 shows that LuC9 bound to affinity-purified anti-Hib PS antibodies from three subjects. Consistent with the RABA inhibition results, LuC9 reacted with solid-phase MAb ED.8 (IgM, K), but not with solid-phase MAb LSF-2 (IgA, A). LuC9 did not bind to human myeloma proteins representative of all the H and L chain isotypes, Ig from three subjects that had been absorbed with Hib PS-agarose, or pooled human IgG (commercial intravenous 'y-globulin) absorbed with Hib PS-agarose.
HibId-J is related to the Hib PS combining site. of Hib PS binding in the RABA (Fig. 4) Scott , D. L. Crimmins, and M. H. Nahm, manuscript in preparation), and they are all consistent with the VKII region being derived from the VKIIA2 gene. The sequences in the first and second framework regions and in the CDR2 and CDR3 regions were identical to the germ-line A2 sequence, with the exception ofone interchange at residue 94 in one ofthe L chains (17) . Fig.  5 shows the partial amino acid sequences of the remaining three purified anti-Hib PS antibodies, DG1, WG1-II, and DG2b. The sequences are consistent with these antibodies being products of the A2 gene.
In a previous report we described a goat polyclonal anti-Id reagent, that specifically inhibited Hib PS binding and reacted with a CRI that predominated the serum anti-Hib PS antibodies of most vaccinated subjects (14) . In the present study, we found that this polyclonal anti-CRI inhibited the Hib PS binding ofonly the VKIIA2 antibodies (data not shown). This result, as well as others described below, indicate that the polyclonal anti-CRI serum is reacting principally with Hibld-l .
HibId-J is localized to the VKIIA2 L chain. To determine whether HibId-1 was present on isolated L chains, or required pairing of H and L, we examined the expression of HibId-l on free H and L chains from purified clonal anti-Hib PS antibodies after SDS-PAGE under reducing conditions. Fig. 6 Dashes indicate identity to A2 sequence. Lower case letters indicate uncertain designation or minor contaminating residues. X indicates no residue identified. X at position 23 is likely an invariant cysteine not identifiable by our sequencing method. Parentheses ( ) refer to possible JK designation based on minor residues identified in JK region.
Hibld-J is prevalent andpredominates the serum anti-Hib PS induced by vaccination. Individual postvaccination sera were analyzed for anti-Hib PS Hibld-1 expression using RABA inhibition by LuC9 (Fig. 7) . 86% of adults and 83% of children, were positive for Hibld-1 anti-Hib PS after vaccination with Hib PS, i.e., subjects having 2 20% of their serum anti-Hib PS antibody activity inhibitable by MAb LuC9. Immunization with Hib PS-DT gave similarly high frequencies of HibId-l positivity in infants (71%), older children (77%), and adults (96%). The fraction of the total serum anti-Hib PS that expressed Hibld-I centered around 60% for all age groups and for both vaccines. There were no significant differences between the mean percent LuC9 inhibition values for the five groups (P > 0.4 by t test), nor was there any correlation between the log of the anti-Hib PS antibody concentration and the LuC9 inhibition value in Hib PS postvaccination sera of children (r = -0.148, P > 0.5) or adults (r = 0.08, P > 0.5).
A comparison was made between the HibId-I anti-Hib PS levels of 88 post-Hib PS vaccination sera from children and adults as determined by LuC9 inhibition and the goat polyclonal anti-CRI inhibition of Hib PS binding in the RABA. The paired inhibition values were highly correlated (r = 0.9, m = 1.04). Thus in keeping with the other comparisons, the dominant Id recognized by the polyclonal anti-CRI reagent appears to be the same or similar to Hibld-1, defined by LuC9.
Differences in Hibld-J expression between pre-andpostvaccination antibodies. The anti-Hib PS Hibld-1 levels were compared between sera obtained from adults before and after vaccination with Hib PS (Fig. 8) . Of 62 subjects, 32 showed a > 20% increase in their Hibld-1 anti-Hib PS level after vaccination. In contrast, only two subjects showed greater than a 20% decrease in serum Hibld-1 anti-Hib PS after vaccination. This relative increase in Hibld-1 after vaccination was also apparent when the data were expressed as percentage of subjects positive for HibId-1 antibodies. Before immunization, 56% of subjects were HibId-1-positive, i.e., had 2 20% oftheir serum anti-Hib (25) . The finding that HibId-1 expression was inhibited by occupancy of the combining site with Hib PS raises the possibility that the Hibld-1 determinant may be near putative contact residues such as the invariant arginine. The availability of anti-idiotypic probes ofdefined specificity permitted us to examine the expression of the VKIIA2 region in the vaccine-induced responses of a large number of subjects. The principal finding was that anti-Hib PS antibodies bearing HibId-l/VKIIA2 were prevalent in the responses induced by both free and DT-conjugated Hib PS, and comprised on the average 60% of the total serum antibody. Neither the frequency of expression nor the predominance of HibId-1 among Hib PS-DT-induced antibodies was significantly different between infants, older children and adults. Previously, we observed that anti-Hib PS antibodies induced in 2-3 mo old infants by immunization with Hib PS conjugated to the outer membrane protein of Neisseria meningitidis, expressed high levels of HibId-1 as detected using the polyclonal anti-CRI reagent, that predominantly recognizes HibId-l (14) . Taken together, these findings indicate that anti-Hib PS antibodies having VKIIA2 L chains dominate both the infant and adult repertoires induced by vaccination. While the recurrence of a particular germ-line encoded V region may appear to be surprising in an outbred human population with high potential for generating antibody diversity, it is consistent with the expression ofconserved V regions by human autoantibodies (26) , and the dominant utilization of a single VL in the murine antibody response to phosphorylcholine (27) .
The predominance of Hibld-l/VKIIA2 antibodies in individual responses to Hib PS, demonstrates the restricted heterogeneity of anti-Hib PS V regions, and is in agreement with isoelectric focusing studies showing that individual anti-Hib PS clonotypes are frequently oligoclonal and may be shared between subjects (20, 28) . Nevertheless, it is important to note that considerable diversity is also present in anti-Hib PS antibodies. Not only can the anti-Hib PS VKIIA2 region associate with several different J regions and thereby generate variability in the third CDR of these antibodies, but anti-Hib PS antibodies may also contain VX, VKI, non A2-VKII, VKIII, and VKIV chains (16, and M. S. Scott et al, manuscript in preparation). The VH chains of anti-Hib PS antibodies have just begun to be scrutinized. They are most commonly restricted to the VHIII subgroup (16) , and by serological analysis they appear related to the VHIII 30P1 and 20P1 genes (29) . Nucleic acid sequence analysis shows that four of five anti-Hib PS hybridomas use a VHIII region having 83-94% homology with the 9.1 (20P1) gene (30) , in conjunction with a variety of D and J elements (31) . Thus, despite the consistent usage and predominance of the VKIIA2 gene product, there is significant VL diversity in the non-A2 antibodies, as well as VH heterogeneity. It will be important to ultimately determine whether this molecular heterogeneity correlates with the observed functional heterogeneity among anti-Hib PS antibodies (1 1, 12) .
The representation of Hibld-1 in the prevaccination or socalled natural anti-Hib PS antibody populations was less than that seen with the vaccine-induced antibodies. The lower expression in prevaccination sera was apparent in both the frequency ofHibld-1-positive subjects as well as in the fraction of the total serum antibody that expressed Hibld- 1 (34) .
In addition to somatic selection ofthe VKIIA2 region, there is the question of evolutionary selection. The VKIIA2 gene is likely to be widely present in the human genome based upon the high frequency of Hibld-1 expression in individual antiHib PS responses. Perhaps the VKIIA2 gene has been selected and maintained in the germ-line because it confers optimal protection against Hib. Such a mechanism has been proposed as an explanation for the conservation of murine germ-line V region genes that encode antibodies reactive with bacterial antigens (35, 36) . However, Hibld-l/VKIIA2-negative antibodies comprise on the average -40% of the vaccine-induced serum anti-Hib PS antibody, and some individuals (probably 10% or less) respond to vaccination with little or no Hibld-1 anti-Hib PS antibody. HibId-I -negative antibodies are probably protective since in vitro they activate complement-mediated bactericidal activity (1 1). Thus, it is questionable whether VKIIA2 antibodies are necessarily more protective than VKIIA2-negative antibodies. An alternative theory for the evolutionary conservation ofthe VKIIA2 gene is that by encoding Hibld-l antibodies, it becomes part ofa functional idiotypic network, and therefore has been selected based upon its idiotopic rather than its paratopic fitness (37, 38) .
A hallmark of the antibody response to Hib PS is age dependence. The ability to produce antibodies in response to immunization with the free polysaccharide does not fully mature until -6 y of age (39, 40). The mechanism(s) of age-related unresponsiveness to free Hib PS is poorly understood. Absence of specific B cells cannot be the explanation as shown by the immunogenicity ofthe conjugate vaccines in infants. Although age-related rearrangement and expression of Ig genes is known to occur (41-44) and has been suggested as a possible mechanism controlling repertoire maturation, the data presented here demonstrate that the VKIIA2 gene product is functionally expressed in infants immunized with conjugate vaccine. In addition, as noted above, anti-Hib PS VH regions may derive from the I.9/20P1 and 30P1 related genes, and these genes are known to be expressed in the fetal repertoire (45) . Therefore, age-related unresponsiveness to free Hib PS does not appear to be related to the inability to generate the appropriate V regions.
